Apolipoprotein B/Apolipoprotein A1 ratio is an independent prognostic factor in pancreatic cancer

IF 5 2区医学 Q2 Medicine

Translational Oncology Pub Date : 2024-11-26 DOI:10.1016/j.tranon.2024.102208

Chenxi Li , Xuhui Yang , Yan Zhong , Wenying Wang , Xin Jin , Lihua Bian , Xiaona Wang

{"title":"Apolipoprotein B/Apolipoprotein A1 ratio is an independent prognostic factor in pancreatic cancer","authors":"Chenxi Li , Xuhui Yang , Yan Zhong , Wenying Wang , Xin Jin , Lihua Bian , Xiaona Wang","doi":"10.1016/j.tranon.2024.102208","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>The relationship between serum lipids and prognosis of pancreatic cancer has not been confirmed. Our purpose in the study was to investigate the associations between serum lipids level and prognosis in patients with pancreatic cancer.</div></div><div><h3>Methods</h3><div>A retrospective study was performed on 286 pancreatic cancer patients who admitted to our hospital from January 1, 2017 to December 31, 2021. Serum lipids level were recorded. Clinical-pathological characteristics, oncologic outcomes, progression free survival (PFS) and overall survival (OS) were collected. The prognostic significance was determined by Kaplan-Meier analysis and Cox proportional hazards regression model.</div></div><div><h3>Results</h3><div>Regarding serum lipids level, compared to normal apolipoprotein B/ apolipoprotein A (ApoB/ApoA1), high ApoB/ApoA1 level indicated a shorter OS (HR:2.028, 95% CI: 1.174–2.504, <em>P</em> = 0.011) and a shorter PFS (HR:1.800, 95% CI: 1.076–3.009, <em>P</em> = 0.025). Other serum lipid molecules were not associated with PFS and OS.</div></div><div><h3>Conclusion</h3><div>ApoB/ApoA1 might be an independent prognostic factor of pancreatic cancer.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"51 ","pages":"Article 102208"},"PeriodicalIF":5.0000,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1936523324003358","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

The relationship between serum lipids and prognosis of pancreatic cancer has not been confirmed. Our purpose in the study was to investigate the associations between serum lipids level and prognosis in patients with pancreatic cancer.

Methods

A retrospective study was performed on 286 pancreatic cancer patients who admitted to our hospital from January 1, 2017 to December 31, 2021. Serum lipids level were recorded. Clinical-pathological characteristics, oncologic outcomes, progression free survival (PFS) and overall survival (OS) were collected. The prognostic significance was determined by Kaplan-Meier analysis and Cox proportional hazards regression model.

Results

Regarding serum lipids level, compared to normal apolipoprotein B/ apolipoprotein A (ApoB/ApoA1), high ApoB/ApoA1 level indicated a shorter OS (HR:2.028, 95% CI: 1.174–2.504, P = 0.011) and a shorter PFS (HR:1.800, 95% CI: 1.076–3.009, P = 0.025). Other serum lipid molecules were not associated with PFS and OS.

Conclusion

ApoB/ApoA1 might be an independent prognostic factor of pancreatic cancer.

查看原文本刊更多论文

载脂蛋白 B/Apolipoprotein A1 比率是胰腺癌的一个独立预后因素

目的血清脂质与胰腺癌预后的关系尚未得到证实。我们的研究旨在探讨胰腺癌患者血清脂质水平与预后之间的关系。记录血清脂质水平。收集了临床病理特征、肿瘤学结果、无进展生存期（PFS）和总生存期（OS）。通过卡普兰-梅耶分析和考克斯比例危险回归模型确定预后意义。结果关于血清脂质水平，与正常载脂蛋白B/载脂蛋白A（载脂蛋白B/载脂蛋白A1）相比，高载脂蛋白B/载脂蛋白A1水平表明OS较短（HR：2.028，95% CI：1.174-2.504，P = 0.011），PFS较短（HR：1.800，95% CI：1.076-3.009，P = 0.025）。结论载脂蛋白B/载脂蛋白A1可能是胰腺癌的一个独立预后因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational Oncology ONCOLOGY-

CiteScore

8.40

自引率

2.00%

发文量

314

审稿时长

54 days

期刊介绍： Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.